Which ASX 200 healthcare shares delivered the top returns in 2020?

COVID-19 created tailwinds for many ASX 200 healthcare shares. Here are the ones that came out on top in 2020.
The post Which ASX 200 healthcare shares delivered the top returns in 2020? appeared first on The Motley Fool Australia. –

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

The onset of a major pandemic last year created tailwinds for many ASX 200 healthcare shares that supported the global effort to tackle COVID-19.

This accelerated the earnings of many ASX 200 healthcare shares, including familiar names such as Resmed Inc (ASX: RMD) and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

However, the ASX 200 healthcare shares that delivered the very top returns in 2020 may come as a surprise.  

Top performing ASX 200 healthcare shares of 2020

1. Polynovo Ltd (ASX: PNV) 

The Polynovo share price doubled in 2020 to find itself as the top performing ASX 200 healthcare share. The company has recently commercialised its NovoSorb BTM product which is used to temporarily close wounds and aid the body in generating new tissue.

NovoSorb BTM has experienced strong sales across approved regions including the United States, Australia, New Zealand, Singapore, India, Taiwan and various countries in the EU. And also pending regulatory approval in Canada and Korea. 

In FY20, Polynovo’s revenues increased 54.6% to $22.2 million, largely driven by the $19.06 million contribution from Novosorb BTM sales. Managing director Paul Brennan has great confidence in the company’s ability to continue grow Novosorb BTM with the expectations to double its revenues in FY21. 

2. Pro Medicus Limited (ASX: PME) 

The Pro Medicus share price has gone from strength to strength in 2020, increasing 50%. The leading provider of radiology information systems has experienced another strong year of growth, with its technology enabling its clients to seamlessly switch to remote reading during COVID-19. 

During the FY20 year, the company announced several new contract wins which have been described as significant in their own right and will make a major contribution to its future revenues. Despite the series of positive new contract wins announced in 2020, the management team is still working on a significant number of new opportunities and its pipeline continues to be strong. 

3. Fisher & Paykel Healthcare Corp Ltd

The Fisher & Paykel share price ran 45% higher in 2020 to record all-time highs, driven by the increased demand for the company’s hospital hardware. In the first half of its 2021 financial year, which ended 30 September 2020, the company’s net profit after tax soared 86% to $225.5 million. 

Looking ahead, the company is making the assumption that its performance in the second half of FY21 will be weaker than 1H21. This is due to hospital hardware returns returning to approximately normal rates combined with reduced diagnosis rates for its obstructive sleep apnea business and elevated freight costs.

Its anticipation of weaker earnings could be the reason why the Fisher & Paykel share price has underperformed other ASX 200 healthcare shares in the second half of 2020.

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Which ASX 200 healthcare shares delivered the top returns in 2020? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!